tbuckley/cabot-search huggingface dataset:
FRI0676 Responsiveness of patient reported outcomes measurement information system (PROMIS®) computerized adaptive tests (CATS) in systemic lupus erythematosus (SLE)
Authors: S. Kasturi, J. Szymonifka, J. Berman, K. Kirou, A. Levine, L. Sammaritano, L. A. Mandl
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> The accurate measurement of patient reported outcomes is a priority for patient-centered care in SLE, a chronic systemic disease with significant impact on quality of life. PROMIS CATs are precise measures of physical, mental, and social health with construct validity in SLE. The longitudinal responsiveness (sensitivity to change) of PROMIS CATs in SLE patients is unknown. <h3>Objectives:</h3> To evaluate the responsiveness of PROMIS CATs in SLE outpatients using patient and physician-derived anchors. <h3>Methods:</h3> Adult SLE patients were recruited from an SLE Center of Excellence. Subjects completed 14 selected PROMIS CATs at two visits a minimum of one month apart. SLE disease activity was measured with a patient global assessment of change, a physician global assessment and the physician-derived SELENA-SLEDAI. Responsiveness of PROMIS scores was evaluated using known-groups validity. Effect sizes were compared across groups of patients who differed in their patient global assessment of change, physician global assessment, and SELENA-SLEDAI using Wilcoxon rank-sum tests. <h3>Results:</h3> A diverse cohort of 228 SLE patients, including 45 (19.8%) patients flaring by SELENA-SLEDAI, completed baseline surveys. Follow up surveys were completed by 190 (83%). There was poor agreement between patient and physician global assessments (weighted kappa statistic [95% CI]=0.16 [0.04–0.28]. Using the patient-based anchor, Anger, Pain Interference, and Physical Function CATs showed low to moderate responsiveness (table 1). Using the physician global assessment, only Anxiety CAT showed low to moderate responsiveness (effect size -0.27, -0.17, and 0.06 [p=0.03] with ≥0.5 point decrease, &lt;0.5 point change, and ≥0.5 point increase respectively), while with the SELENA-SLEDAI as anchor, only Applied Cognition-Abilities CAT showed responsiveness (0.34, -0.01, 0.0 [p&lt;0.01] with ≥3 point decrease, &lt;3 point change, and ≥3 point increase respectively). <h3>Conclusions:</h3> PROMIS CATs showed modest responsiveness to patient-reported, but generally not physician-derived changes in lupus health status in domains of anger, pain interference, and physical function. These data suggest that certain PROMIS CATs are precise and sensitive tools which may be used to measure and monitor important aspects of the patient experience of lupus not captured by physician-derived metrics. Further studies are needed to evaluate the responsiveness of PROMIS CATs in populations with greater SLE disease activity and more regular follow up. <h3>Acknowledgements:</h3> Funding was provided by the Rheumatology Research Foundation Scientist Development Award. <h3>Disclosure of Interest:</h3> None declared
AB1046 Allopurinol use in chronic kidney disease- is there a difference in achieving target uric acid?- a retrospective study
Authors: V.R. Mehta, R. Peredo-Wende, R. Peredo-Wende
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with gout are recommended to treat to target uric acid level of 6 mg/dL in absence of tophi, and &lt;5 mg/dL if tophi present. A case-controlled retrospective analysis by Stamp et al of allopurinol hypersensitivity reaction confirmed that the highest risk of severe hypersensitivity reaction is in the first few months of therapy and thus a low starting dose is recommended (as low as 50 mg in stage 4 chronic kidney disease and worse). Due to concerns related to adverse effects from Allopurinol, we hypothesised that allopurinol use would be less aggressive in terms of achieving target uric acid. <h3>Objectives</h3> We aim to compare the frequency of achieving target uric acid level in patients with glomerular filtration rate (GFR) of less than 60 and more than 60. <h3>Methods</h3> We reviewed charts of patients in a large private practice who were prescribed Allopurinol. Patients who had at least atleast two office visits and had been on Allopurinol at least six months were included in the study. Charts were reviewed of patients for uric acid level, Allopurinol dose, GFR and any major adverse events. Major allopurinol related adverse event was defined as any adverse event leading to hospitalisation or cessation of medication. <h3>Results</h3> Mean Allopurinol dose for patients with GFR of more than 60 was 244. There were no major adverse events and 52 out of total 103 patients (50.5%) had achieved goal uric acid. Mean Allopurinol dose for patients with GFR of less than 60 was 238. There were no major adverse events and 19 out of total 38 patients (50%) had achieved goal uric acid. <h3>Conclusions</h3> There was no difference noted in patient with GFR less than 60 or more than 60 in terms of achieving goal uric acid level. No major adverse events were noted in either group. <h3>Disclosure of Interest</h3> None declared
Abstract P027: Obesity Treatment-Induced Weight Loss Improves Resting Blood Pressure and Reduces Progression from Prehypertension to Hypertension in Overweight/Obese Adults
Authors: Alok K Gupta, Timothy Church, Wesley W Day
Journal: Circulation (2013)

Background: Obesity is associated with increased risk of hypertension (HTN). Weight loss can reduce blood pressure (BP) and prevent progression to HTN. In the CONQUER trial, overweight/obese subjects with ≥2 weight-related comorbidities had significant weight loss over 56 weeks with phentermine plus topiramate extended-release (PHEN/TPM ER) vs placebo when used in combination with a program of lifestyle modifications. Methods: This post hoc analysis of CONQUER evaluated the effects of PHEN/TPM ER on weight, BP, and HTN status over 56 weeks (intent-to-treat population with last observation carried forward). Overweight/obese subjects with normotension (systolic BP/diastolic BP&lt;120/80 mm Hg; 8.7%; n=212), preHTN (120-139/80-89 mm Hg; 19.0%; n=465: both without antiHTN medication use), and HTN (≥140/90 or antiHTN medication use; 72.3%; n=1770) were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92). Results: At week 56, PHEN/TPM ER-treated subjects in all categories (normotension, preHTN, HTN) achieved significant weight loss vs placebo (percentage and absolute; all P &lt;.0001). Systolic BP was improved vs placebo in all categories in subjects receiving PHEN/TPM ER (significant vs placebo in 15/92 group; Table). Fewer subjects with normotension at baseline receiving PHEN/TPM ER progressed to preHTN, and fewer with preHTN at baseline progressed to HTN, vs placebo (Table). A greater percentage of PHEN/TPM ER-treated subjects with preHTN and HTN achieved normotension vs placebo. Most common adverse events in subjects with preHTN and HTN were constipation, dry mouth, and paraesthesia, and in those with normotension were upper respiratory tract infection, dry mouth, and paraesthesia. Conclusion: Overweight/obese subjects treated with PHEN/TPM ER plus lifestyle intervention lost more body weight vs placebo over 56 weeks. This weight loss occurred along with improvements in BP in subjects with normotension, preHTN, and HTN, potentially improving cardiovascular risk.
FRI0031 Change in functional disability in acpa-positive arthralgia patients prior to progression to inflammatory arthritis
Authors: P. Pentony, S. Twigg, J.L. Nam, K. Mankia, L. Hunt, E.M. Hensor, P. Emery
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Only one study<sup>1</sup> has assessed functional limitation in the pre-clinical phase of rheumatoid arthritis. Finding that functional limitations already exist during the symptomatic pre-arthritis phase. It is unclear if patient reported outcomes (PROs) are associated with progression to inflammatory arthritis (IA). <h3>Objectives</h3> To assess baseline and change in PROs in the lead up to progression to IA and its association with progression to IA. <h3>Methods</h3> From June 2008 to August 2016, 205 CCP positive patients without clinical synovitis were observed 3 monthly for 12 months and then as clinically indicated. The end point was development of IA within 12 months. PROs including HAQ, fatigue VAS, disease activity (DA) VAS and pain VAS were recorded at each visit. Cox regression was used to assess the association of each PRO at baseline with progression, then latent growth curves (LGC) were constructed to model change in PRO over time. The LGC were added as covariates in the cox regression models to determine whether changes in PROs over 12 months were associated with progression. <h3>Results</h3> 204 anti-CCP positive cases were included (one case excluded as had only baseline data). Of these, 50 developed IA within 12 months. Estimated mean baseline HAQ was 0.53 (Standard Error, SE 0.04) and mean increase in HAQ 0.06 per 12 months (SE 0.04). Mean baseline fatigue and pain VAS were 32 mm and 28 mm, respectively (SE 1.8 and 1.6, respectively). Mean increases in fatigue and pain per 12 months were 3.9 mm (SE 2.6) and 3.5 mm (SE 2.1), respectively. Table 1 shows how hazard ratios for progression IA relate to baseline and change in HAQ and VAS. Hazards for progression to IA were increased with greater baseline fatigue VAS, and greater rate of increase in reported functional impairment, fatigue and pain. <h3>Conclusions</h3> Greater rates of increase in HAQ, fatigue and pain VAS were associated with small, but statistically significant increases in hazards of progression. Therefore, patient reported measures may be helpful for risk stratification in patients with positive anti-CCP. <h3>Reference</h3> [1] ten Brinck RM vSH, Mangnus L, Burgers LE, Reijnierse M, Huizinga TW, van der Helm-van Mil AH. Functional Disability in Patients Presenting with Clinically Suspect Arthralgia and Progression to Clinical Arthritis [abstract]. Arthritis Rheumatol. 2016;68(supl 10). <h3>Acknowledgements</h3> The authors would like to thank all the participating general practitioners and health professionals and the UK Clinical Research Network teams for the referrals from primary care to the study <h3>Disclosure of Interest</h3> None declared
The evolution of the<i>European Respiratory Journal</i>: volume 2
Authors: James D. Chalmers, Martin Kolb
Journal: European Respiratory Journal (2019)

At the start of this, our second year in charge of the European Respiratory Journal , we want to take this opportunity to wish all of our readers, authors, reviewers and editors a very happy and successful 2019. It has been a busy and successful year at the journal with a record impact (more on this to come), exciting new series, excellent science and the addition of a few new faces at the journal. Here we present our review of 2018 and highlight some of the new features at the journal and what readers can expect from the ERJ in 2019. The European Respiratory Journal review of 2018 <http://ow.ly/FELu30ndxHN>
Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Erika J. Crosby, William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, Terry Hyslop, Sungjin Kim, Andre Rogatko, Veronica Lubkov, Joshua C. Snyder, Takuya Osada, Amy C. Hobeika, Michael A. Morse, H. Kim Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines targeting established oncogenic drivers such as the genomic amplification of HER2. We constructed a vaccine based on a novel alphaviral vector encoding a portion of HER2 (VRP-HER2). Patients and Methods: In preclinical studies, mice were immunized with VRP-HER2 before or after implantation of hHER2+ tumor cells and HER2-specific immune responses and antitumor function were evaluated. We tested VRP-HER2 in a phase I clinical trial where subjects with advanced HER2-overexpressing malignancies in cohort 1 received VRP-HER2 every 2 weeks for a total of 3 doses. In cohort 2, subjects received the same schedule concurrently with a HER2-targeted therapy. Results: Vaccination in preclinical models with VRP-HER2 induced HER2-specific T cells and antibodies while inhibiting tumor growth. VRP-HER2 was well tolerated in patients and vaccination induced HER2-specific T cells and antibodies. Although a phase I study, there was 1 partial response and 2 patients with continued stable disease. Median OS was 50.2 months in cohort 1 (n = 4) and 32.7 months in cohort 2 (n = 18). Perforin expression by memory CD8 T cells post-vaccination significantly correlated with improved PFS. Conclusions: VRP-HER2 increased HER2-specific memory CD8 T cells and had antitumor effects in preclinical and clinical studies. The expansion of HER2-specific memory CD8 T cells in vaccinated patients was significantly correlated with increased PFS. Subsequent studies will seek to enhance T-cell activity by combining with anti-PD-1.
Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency
Authors: Jen-hwa Chu, Wenlan Zang, Milica Vukmirovic, Xiting Yan, Taylor Adams, Giuseppe DeIuliis, Buqu Hu, Antun Mihaljinec, Jonas C Schupp, Michael J Becich, Harry Hochheiser, Kevin F Gibson, Edward S Chen, Alison Morris, Joseph K Leader, Stephen R Wisniewski, Yingze Zhang, Frank C Sciurba, Ronald G Collman, Robert Sandhaus, Erica L Herzog, Karen C Patterson, Maor Sauler, Charlie Strange, Naftali Kaminski
Journal: Thorax (2020)

Background Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that causes early onset pulmonary emphysema and airways obstruction. The complete mechanisms via which AATD causes lung disease are not fully understood. To improve our understanding of the pathogenesis of AATD, we investigated gene expression profiles of bronchoalveolar lavage (BAL) and peripheral blood mononuclear cells (PBMCs) in AATD individuals. Methods We performed RNA-Seq on RNA extracted from matched BAL and PBMC samples isolated from 89 subjects enrolled in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Subjects were stratified by genotype and augmentation therapy. Supervised and unsupervised differential gene expression analyses were performed using Weighted Gene Co-expression Network Analysis (WGCNA) to identify gene profiles associated with subjects’ clinical variables. The genes in the most significant WGCNA module were used to cluster AATD individuals. Gene validation was performed by NanoString nCounter Gene Expression Assay. Result We observed modest effects of AATD genotype and augmentation therapy on gene expression. When WGCNA was applied to BAL transcriptome, one gene module, ME31 (2312 genes), correlated with the highest number of clinical variables and was functionally enriched with numerous immune T-lymphocyte related pathways. This gene module identified two distinct clusters of AATD individuals with different disease severity and distinct PBMC gene expression patterns. Conclusions We successfully identified novel clusters of AATD individuals where severity correlated with increased immune response independent of individuals’ genotype and augmentation therapy. These findings may suggest the presence of previously unrecognised disease endotypes in AATD that associate with T-lymphocyte immunity and disease severity.
Abstract 17271: Optimising Physiological Assessment of Serial Coronary Artery Lesions Using an in vitro 3-D Printed Model of Tandem Stenoses
Authors: Bhavik N Modi, Anjalee Chattersingh, Kseniia Eruslanova, Matthew Ryan, Howard Ellis, Jack Lee, Phil Chowienczyk, Divaka Perera
Journal: Circulation (2017)

Introduction: Fractional Flow Reserve (FFR) is considered the optimal technique to assess physiological significance of coronary artery disease during angiography. However, the ability of pressure-derived indices to assess individual lesions is unclear due to potential haemodynamic interplay between serial stenoses. The most common technique uses trans-lesional change in FFR (ΔFFR) on pressure wire pullback to estimate significance of each lesion. We aimed to evaluate determinants of this interplay and incorporate these into a model predicting the true significance of a stenosis, once an accompanying stenosis is removed. Methods: Coronary arteries with tandem stenoses were modelled using 3D-printing in various configurations of lesion severity, length and separation. Using a validated in vitro model of coronary circulation, 52 configurations of tandem stenoses were assessed by pressure wire pullback and compared with tubes containing isolated stenoses. The functional significance of isolated stenoses (FFR...
Multiple Lesions in Irradiated Skin
Authors: Megan Wetzel, Jae Y. Jung, Timothy S. Brown
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia
Authors: Ivana Djuretic, Veena Krishnamoorthy, Cesar Sommer, Danielle E. Dettling, Kris Poulsen, Wei Chen, Wenyue Hu, Allison Given Chunyk, Kevin Lindquist, Shobha Potluri, Robert C Rickert, Barbra Sasu, Javier Chaparro-Riggers, Yik Andy Yeung
Journal: Blood (2018)
Risk of Appendicitis in IgE-Mediated Allergy
Authors: Martin Dahlberg, Åsa H. Everhov
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
AB0490 Evaluation of inhibitory factor of radiographic progression by iguratimod add-on therapy in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
Authors: K. Katayama, Y. Kon, T. Okubo, R. Fukai, Y. Makino, H. Ito
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Iguratimod (IGU) is one of csDMARDs (Conventional synthetic Disease modified anti-rheumatoid arthritis drug) for RA patients in Japan. It was reported to suppress the production of inflammatory cytokines by inhibiting NFkB pass-way. IGU add-on therapy was efficient in patients with RA who were previously designated MTX-monotherapy inadequate responders (MTX-IR). The efficacy of IGU add-on therapy in bDMARDs (Biological DMARD)-IR patients was also reported. In this study, we showed disease activity and safety, and showed also radiographic evaluation for the first time by adding IGU. <h3>Objectives</h3> To obtain DAS28-ESR and adverse event data about adding IGU on RA patients with poor response to csDMRADs and/or bDMARDs in single-centre, open label and retrospective study. Furthermore, to show the radiological evaluation after one year. <h3>Methods</h3> Clinical and radiographic efficacy was assessed by disease activity score of 28 joints (DAS28) ESR (n=68) and the modified total Sharp score (mTSS) (n=44), respectively. We <b><i>evaluated</i></b> which <b><i>factors</i></b> are important in determining a <b><i>prognosis of clinical response and mTSS.</i></b> For safety, adverse events (AE) were investigated on all patients (n=89). <h3>Results</h3> 89 RA patients were recruited, and male was 28% (n=25). Mean age was 61.5 years old and mean of disease duration was 87 months. Main csDMARDs were MTX (72%). The mean dose of MTX was 7 mg/week (The average dose in Japan). Observational period was 13 months (range, 1 to 30). DAS28-ESR changed from 4.3±1.1 to 3.6±1.2 after adding IGU for 6 months (p&lt;0.0001). The relation with the predictive factors before treatment and the response by using Iguratimod. CRP, ESR, swelling joint, DAS28-ESR, CDAI and VAS at the baseline were all significantly high in Response (good response+ moderate response) group than No-response group (table 1). Yearly mTSS was 0.60 and rate of structural remission (mTSS ≤0.5) <i>was</i> 87%. Rapid radiological progression was not seen even if yearly mTSS at the baseline was 5.52. The relation between yearly mTSS and disease duration was shown in Figure (r=0.33, p=0.029). Adverse AE were observed such as transaminase elevation, stomatitis and dizziness. All AE was not serious. DAS28-ESR, CRP, ESR and swelling joint were prognostic factors of the group of good and moderate response against no response group. <h3>Conclusions</h3> Adding IGU to csDMARDs with poor response in RA patients is effective, but AE should be considered. Radiographic progression by Iguratimod might be inhibited in early phase of RA. <h3>Disclosure of Interest</h3> None declared
Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Tim H Brümmendorf, Carla M. Mamolo, Arlene Reisman, Andrew G Bushmakin, Joseph C Cappelleri, Rocco J. Crescenzo, Liza DeAnnuntis, Andrea Viquiera, Jorge E. Cortes
Journal: Blood (2018)
SP0014 Health professionals in rheumatology welcome
Authors: R.H. Moe
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> An increasing amount of people are diagnosed with Rheumatic and Musculoskeletal Diseases (RMDs). EULAR Health Professionals in Rheumatology (HPR) can through substantial knowledge and clinical expertise contribute significantly to better lives with RMDs. Examples of important HPR core competencies are education, evidence-based treatment, prevention, team-based rehabilitation, and the support of individuals to participate in work, or education. The presentation will address some of the important multidisciplinary contributions to reduce the individual and societal burden of RMDs in the future. <h3>Disclosure of Interest</h3> None declared